204 related articles for article (PubMed ID: 20053328)
1. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
Bacher U; Haferlach C; Kröger N; Schnittger S; Kern W; Wiedemann B; Zander AR; Haferlach T
Biol Blood Marrow Transplant; 2010 Jan; 16(1):1-11. PubMed ID: 20053328
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the prognosis of patients with myelodysplastic syndromes.
Aul C; Giagounidis A; Germing U; Ganser A
Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
Panani AD; Roussos C
Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
[TBL] [Abstract][Full Text] [Related]
6. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
Cermák J; Vítek A; Michalová K
Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of cytogenetics in myelodysplastic syndromes.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplasia: when to treat and how.
Larson RA
Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
[TBL] [Abstract][Full Text] [Related]
10. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes.
Schiffer CA
Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
12. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
13. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
14. Refractory anemia and the myelodysplastic syndromes.
Lawrence LW
Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.
Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A
Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099
[TBL] [Abstract][Full Text] [Related]
16. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
17. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
18. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.
Komrokji RS; Bennett JM
Curr Hematol Rep; 2005 May; 4(3):175-81. PubMed ID: 15865868
[TBL] [Abstract][Full Text] [Related]
19. Transplantation strategies for the management of patients with myelodysplastic syndromes.
Meletis J; Terpos E
J BUON; 2009; 14(4):551-64. PubMed ID: 20148443
[TBL] [Abstract][Full Text] [Related]
20. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
